よむ、つかう、まなぶ。
05参考資料 帯状疱疹ワクチンファクトシート第二版［3.2MB］ (75 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_47466.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会（第65回 12／18）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
Belgium. Epidemiol Infect 2012; 140(11): 2096-109.
127.
Brisson M, Edmunds WJ. Epidemiology of Varicella-Zoster Virus in England and Wales. J Med Virol 2003; 70
Suppl 1: S9-14.
128.
Hata A, Inoue F, Yamasaki M, et al. Safety, humoral and cell-mediated immune responses to herpes zoster vaccine
in subjects with diabetes mellitus. J Infect 2013; 67(3): 215-9.
129.
Kumakura S, Shibata H, Onoda K, Nishimura N, Matsuda C, Hirose M. Seroprevalence survey on measles,
mumps, rubella and varicella antibodies in healthcare workers in Japan: sex, age, occupational-related differences
and vaccine efficacy. Epidemiol Infect 2014; 142(1): 12-9.
130.
神谷齊, 浅野喜造, 尾崎隆男, et al. 水痘ワクチンの力価と流通時のワクチン力価の安定性. 感染症学雑
誌 2011; 85(2): 161-5.
131.
独立行政法人医薬品医療機器総合機構. 審査報告書．乾燥組換え帯状疱疹ワクチン（チャイニーズハム
スター卵巣細胞由来）シングリックス筋注用
令和 5 年 5 月 11 日.
https://www.pmda.go.jp/drugs/2023/P20230628003/340278000_23000AMX00460_A100_1.pdf (accessed
2024/04/26).
132.
Sarkadi J, Jankovics M, Fodor K, et al. High-level cellular and humoral immune responses in Guinea pigs
immunized intradermally with a heat-inactivated varicella-zoster virus vaccine. Clin Vaccine Immunol 2015; 22(5):
570-7.
133.
Levine MJ, Ellison MC, Zerbe GO, et al. Comparison of a live attenuated and an inactivated varicella vaccine to
boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine 2000; 18(25):
2915-20.
134.
Mullane KM, Winston DJ, Wertheim MS, et al. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT)
in immunocompromised adults. J Infect Dis 2013; 208(9): 1375-85.
135.
Merck & Co., Inc. In First Phase 3 Trial, Merck’s Investigational Inactivated Varicella Zoster Virus Vaccine
(V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in
Immunocompromised Subjects. 2017.
136.
Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older
adults. N Engl J Med 2005; 352(22): 2271-84.
137.
Schmader KE, Levin MJ, Gnann JW, Jr., et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons
aged 50-59 years. Clin Infect Dis 2012; 54(7): 922-8.
138.
Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen SJ. Herpes zoster vaccine in older adults and the risk
of subsequent herpes zoster disease. Jama 2011; 305(2): 160-6.
139.
Leroux-Roels I, Leroux-Roels G, Clement F, et al. A phase 1/2 clinical trial evaluating safety and immunogenicity
of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis 2012; 206(8):
1280-90.
140.
Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.
N Engl J Med 2015; 372(22): 2087-96.
141.
Cunningham AL. The herpes zoster subunit vaccine. Expert Opin Biol Ther 2016; 16(2): 265-71.
142.
Berkowitz EM, Moyle G, Stellbrink HJ, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit
73
127.
Brisson M, Edmunds WJ. Epidemiology of Varicella-Zoster Virus in England and Wales. J Med Virol 2003; 70
Suppl 1: S9-14.
128.
Hata A, Inoue F, Yamasaki M, et al. Safety, humoral and cell-mediated immune responses to herpes zoster vaccine
in subjects with diabetes mellitus. J Infect 2013; 67(3): 215-9.
129.
Kumakura S, Shibata H, Onoda K, Nishimura N, Matsuda C, Hirose M. Seroprevalence survey on measles,
mumps, rubella and varicella antibodies in healthcare workers in Japan: sex, age, occupational-related differences
and vaccine efficacy. Epidemiol Infect 2014; 142(1): 12-9.
130.
神谷齊, 浅野喜造, 尾崎隆男, et al. 水痘ワクチンの力価と流通時のワクチン力価の安定性. 感染症学雑
誌 2011; 85(2): 161-5.
131.
独立行政法人医薬品医療機器総合機構. 審査報告書．乾燥組換え帯状疱疹ワクチン（チャイニーズハム
スター卵巣細胞由来）シングリックス筋注用
令和 5 年 5 月 11 日.
https://www.pmda.go.jp/drugs/2023/P20230628003/340278000_23000AMX00460_A100_1.pdf (accessed
2024/04/26).
132.
Sarkadi J, Jankovics M, Fodor K, et al. High-level cellular and humoral immune responses in Guinea pigs
immunized intradermally with a heat-inactivated varicella-zoster virus vaccine. Clin Vaccine Immunol 2015; 22(5):
570-7.
133.
Levine MJ, Ellison MC, Zerbe GO, et al. Comparison of a live attenuated and an inactivated varicella vaccine to
boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine 2000; 18(25):
2915-20.
134.
Mullane KM, Winston DJ, Wertheim MS, et al. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT)
in immunocompromised adults. J Infect Dis 2013; 208(9): 1375-85.
135.
Merck & Co., Inc. In First Phase 3 Trial, Merck’s Investigational Inactivated Varicella Zoster Virus Vaccine
(V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in
Immunocompromised Subjects. 2017.
136.
Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older
adults. N Engl J Med 2005; 352(22): 2271-84.
137.
Schmader KE, Levin MJ, Gnann JW, Jr., et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons
aged 50-59 years. Clin Infect Dis 2012; 54(7): 922-8.
138.
Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen SJ. Herpes zoster vaccine in older adults and the risk
of subsequent herpes zoster disease. Jama 2011; 305(2): 160-6.
139.
Leroux-Roels I, Leroux-Roels G, Clement F, et al. A phase 1/2 clinical trial evaluating safety and immunogenicity
of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis 2012; 206(8):
1280-90.
140.
Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.
N Engl J Med 2015; 372(22): 2087-96.
141.
Cunningham AL. The herpes zoster subunit vaccine. Expert Opin Biol Ther 2016; 16(2): 265-71.
142.
Berkowitz EM, Moyle G, Stellbrink HJ, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit
73